Does Rallies show Form 4 insider transactions for ARTV?

Yes. Rallies tracks ARTV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ARTV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARTV. It does not provide personalized investment advice.

ARTV (Artiva Biotherapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a publicly traded Healthcare sector company. As of May 21, 2026, ARTV trades at $7.81 with a market cap of $447.98M and a P/E ratio of -2.27. ARTV moved -8.60% today. Year to date, ARTV is +88.01%; over the trailing twelve months it is +262.96%. Its 52-week range spans $1.47 to $17.31. Analyst consensus is strong buy with an average price target of $35.00. Rallies surfaces ARTV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ARTV stock inside the company?

Recent ARTV insider activity includes Raymon Heather sold 3.10K, Horan Christopher sold 7.00K, Bush Jennifer sold 8.79K, Banerjee Subhashis sold 7.04K, and Aslan Fred sold 27.12K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ARTV Key Metrics

Key financial metrics for ARTV
Metric	Value
Price	$7.81
Market Cap	$447.98M
P/E Ratio	-2.27
EPS	$-3.43
Dividend Yield	0.00%
52-Week High	$17.31
52-Week Low	$1.47
Volume	1.93K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-83.86M
Gross Margin	0.00%

Recent ARTV Insider Trades

Raymon Heather sold 3.10K (~$27.88K) on May 19, 2026.
Horan Christopher sold 7.00K (~$63.07K) on May 19, 2026.
Bush Jennifer sold 8.79K (~$79.18K) on May 19, 2026.
Banerjee Subhashis sold 7.04K (~$63.39K) on May 19, 2026.
Aslan Fred sold 27.12K (~$244.25K) on May 19, 2026.

Latest ARTV News

Artiva’s AlloNK Shows 71% ACR50 Response, $300M Raise Fuels Phase 3 Trial — May 8, 2026
Artiva Biotherapeutics Targets 50% ACR50 in RA After Pivot, Holds $123M Runway — Mar 4, 2026
Artiva Biotherapeutics Names 35-Year Pharma Veteran Elaine Sorg Ahead of AlloNK Data — Feb 19, 2026
Artiva Biotherapeutics Earns $19 Consensus Target while Shares Fall 5.7% — Jan 16, 2026
Analysts Set $19 Consensus Price Target for Artiva Biotherapeutics — Jan 16, 2026

ARTV Analyst Consensus

6 analysts cover ARTV: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.00.

Common questions about ARTV

Who is trading ARTV stock inside the company?: Recent ARTV insider activity includes Raymon Heather sold 3.10K, Horan Christopher sold 7.00K, Bush Jennifer sold 8.79K, Banerjee Subhashis sold 7.04K, and Aslan Fred sold 27.12K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ARTV?: Yes. Rallies tracks ARTV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ARTV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARTV. It does not provide personalized investment advice.